Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma

Jason E. Knuffman, Christine A. Sorkness, Robert F. Lemanske, David T. Mauger, Susan J. Boehmer, Fernando Martinez, Leonard B. Bacharier, Robert C. Strunk, Stanley J. Szefler, Robert S. Zeiger, Lynn M. Taussig

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Background: In children with mild-to-moderate persistent asthma, identification of phenotypic predictors to guide selection of a controller regimen is essential. Objective: We sought to identify phenotypic characteristics having predictive value for the difference in treatment responses between twice-daily fluticasone and once-daily montelukast. Methods: Data from the Pediatric Asthma Controller Trial were assessed with multivariate analysis. Outcomes included the change in asthma control days (ACDs), FEV1, peak expiratory flow, and time to first asthma exacerbation measured over a 1-year treatment period. Results: The mean age was 9.6 ± 2.1 years, 60% were male, 50% had a parental history of asthma, and 78% had positive aeroallergen skin prick test responses. The mean percent predicted prebronchodilator FEV1 was 97.8% ± 12.9%, the median PC20 value was 0.93 mg/mL, and the median exhaled nitric oxide (eNO) level was 25.2 ppb. A history of parental asthma best predicted the expected treatment benefit with fluticasone compared with montelukast in terms of gain in ACDs (adjusted P = .02) and time to first exacerbation (adjusted P = .05). Increased baseline eNO levels predicted the differential treatment response for fluticasone regarding the gain in ACDs (adjusted P = .01). Prior inhaled corticosteroid (ICS) use (adjusted P = .01) and low PC20 values (adjusted P = .03) each predicted the expected treatment benefit with fluticasone over montelukast regarding time to first exacerbation. No phenotypic characteristics predicted treatment benefits for montelukast over fluticasone for either outcome. Conclusions: Physicians treating children with a parental history of asthma, increased eNO levels, low PC20 values, or a history of ICS use can expect the best long-term outcomes with ICS therapy compared with treatment with leukotriene receptor antagonists.

Original languageEnglish (US)
Pages (from-to)411-416
Number of pages6
JournalJournal of Allergy and Clinical Immunology
Volume123
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Leukotrienes
montelukast
Adrenal Cortex Hormones
Asthma
Pediatrics
Nitric Oxide
Therapeutics
Leukotriene Antagonists
Skin Tests
Multivariate Analysis
Fluticasone
Physicians

Keywords

  • Asthma
  • biomarkers
  • exhaled nitric oxide
  • fluticasone propionate
  • inhaled corticosteroids
  • montelukast
  • pulmonary response

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. / Knuffman, Jason E.; Sorkness, Christine A.; Lemanske, Robert F.; Mauger, David T.; Boehmer, Susan J.; Martinez, Fernando; Bacharier, Leonard B.; Strunk, Robert C.; Szefler, Stanley J.; Zeiger, Robert S.; Taussig, Lynn M.

In: Journal of Allergy and Clinical Immunology, Vol. 123, No. 2, 02.2009, p. 411-416.

Research output: Contribution to journalArticle

Knuffman, JE, Sorkness, CA, Lemanske, RF, Mauger, DT, Boehmer, SJ, Martinez, F, Bacharier, LB, Strunk, RC, Szefler, SJ, Zeiger, RS & Taussig, LM 2009, 'Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma', Journal of Allergy and Clinical Immunology, vol. 123, no. 2, pp. 411-416. https://doi.org/10.1016/j.jaci.2008.11.016
Knuffman, Jason E. ; Sorkness, Christine A. ; Lemanske, Robert F. ; Mauger, David T. ; Boehmer, Susan J. ; Martinez, Fernando ; Bacharier, Leonard B. ; Strunk, Robert C. ; Szefler, Stanley J. ; Zeiger, Robert S. ; Taussig, Lynn M. / Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. In: Journal of Allergy and Clinical Immunology. 2009 ; Vol. 123, No. 2. pp. 411-416.
@article{60f2075b0a5f4e8b87b6795ef2aebfda,
title = "Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma",
abstract = "Background: In children with mild-to-moderate persistent asthma, identification of phenotypic predictors to guide selection of a controller regimen is essential. Objective: We sought to identify phenotypic characteristics having predictive value for the difference in treatment responses between twice-daily fluticasone and once-daily montelukast. Methods: Data from the Pediatric Asthma Controller Trial were assessed with multivariate analysis. Outcomes included the change in asthma control days (ACDs), FEV1, peak expiratory flow, and time to first asthma exacerbation measured over a 1-year treatment period. Results: The mean age was 9.6 ± 2.1 years, 60{\%} were male, 50{\%} had a parental history of asthma, and 78{\%} had positive aeroallergen skin prick test responses. The mean percent predicted prebronchodilator FEV1 was 97.8{\%} ± 12.9{\%}, the median PC20 value was 0.93 mg/mL, and the median exhaled nitric oxide (eNO) level was 25.2 ppb. A history of parental asthma best predicted the expected treatment benefit with fluticasone compared with montelukast in terms of gain in ACDs (adjusted P = .02) and time to first exacerbation (adjusted P = .05). Increased baseline eNO levels predicted the differential treatment response for fluticasone regarding the gain in ACDs (adjusted P = .01). Prior inhaled corticosteroid (ICS) use (adjusted P = .01) and low PC20 values (adjusted P = .03) each predicted the expected treatment benefit with fluticasone over montelukast regarding time to first exacerbation. No phenotypic characteristics predicted treatment benefits for montelukast over fluticasone for either outcome. Conclusions: Physicians treating children with a parental history of asthma, increased eNO levels, low PC20 values, or a history of ICS use can expect the best long-term outcomes with ICS therapy compared with treatment with leukotriene receptor antagonists.",
keywords = "Asthma, biomarkers, exhaled nitric oxide, fluticasone propionate, inhaled corticosteroids, montelukast, pulmonary response",
author = "Knuffman, {Jason E.} and Sorkness, {Christine A.} and Lemanske, {Robert F.} and Mauger, {David T.} and Boehmer, {Susan J.} and Fernando Martinez and Bacharier, {Leonard B.} and Strunk, {Robert C.} and Szefler, {Stanley J.} and Zeiger, {Robert S.} and Taussig, {Lynn M.}",
year = "2009",
month = "2",
doi = "10.1016/j.jaci.2008.11.016",
language = "English (US)",
volume = "123",
pages = "411--416",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma

AU - Knuffman, Jason E.

AU - Sorkness, Christine A.

AU - Lemanske, Robert F.

AU - Mauger, David T.

AU - Boehmer, Susan J.

AU - Martinez, Fernando

AU - Bacharier, Leonard B.

AU - Strunk, Robert C.

AU - Szefler, Stanley J.

AU - Zeiger, Robert S.

AU - Taussig, Lynn M.

PY - 2009/2

Y1 - 2009/2

N2 - Background: In children with mild-to-moderate persistent asthma, identification of phenotypic predictors to guide selection of a controller regimen is essential. Objective: We sought to identify phenotypic characteristics having predictive value for the difference in treatment responses between twice-daily fluticasone and once-daily montelukast. Methods: Data from the Pediatric Asthma Controller Trial were assessed with multivariate analysis. Outcomes included the change in asthma control days (ACDs), FEV1, peak expiratory flow, and time to first asthma exacerbation measured over a 1-year treatment period. Results: The mean age was 9.6 ± 2.1 years, 60% were male, 50% had a parental history of asthma, and 78% had positive aeroallergen skin prick test responses. The mean percent predicted prebronchodilator FEV1 was 97.8% ± 12.9%, the median PC20 value was 0.93 mg/mL, and the median exhaled nitric oxide (eNO) level was 25.2 ppb. A history of parental asthma best predicted the expected treatment benefit with fluticasone compared with montelukast in terms of gain in ACDs (adjusted P = .02) and time to first exacerbation (adjusted P = .05). Increased baseline eNO levels predicted the differential treatment response for fluticasone regarding the gain in ACDs (adjusted P = .01). Prior inhaled corticosteroid (ICS) use (adjusted P = .01) and low PC20 values (adjusted P = .03) each predicted the expected treatment benefit with fluticasone over montelukast regarding time to first exacerbation. No phenotypic characteristics predicted treatment benefits for montelukast over fluticasone for either outcome. Conclusions: Physicians treating children with a parental history of asthma, increased eNO levels, low PC20 values, or a history of ICS use can expect the best long-term outcomes with ICS therapy compared with treatment with leukotriene receptor antagonists.

AB - Background: In children with mild-to-moderate persistent asthma, identification of phenotypic predictors to guide selection of a controller regimen is essential. Objective: We sought to identify phenotypic characteristics having predictive value for the difference in treatment responses between twice-daily fluticasone and once-daily montelukast. Methods: Data from the Pediatric Asthma Controller Trial were assessed with multivariate analysis. Outcomes included the change in asthma control days (ACDs), FEV1, peak expiratory flow, and time to first asthma exacerbation measured over a 1-year treatment period. Results: The mean age was 9.6 ± 2.1 years, 60% were male, 50% had a parental history of asthma, and 78% had positive aeroallergen skin prick test responses. The mean percent predicted prebronchodilator FEV1 was 97.8% ± 12.9%, the median PC20 value was 0.93 mg/mL, and the median exhaled nitric oxide (eNO) level was 25.2 ppb. A history of parental asthma best predicted the expected treatment benefit with fluticasone compared with montelukast in terms of gain in ACDs (adjusted P = .02) and time to first exacerbation (adjusted P = .05). Increased baseline eNO levels predicted the differential treatment response for fluticasone regarding the gain in ACDs (adjusted P = .01). Prior inhaled corticosteroid (ICS) use (adjusted P = .01) and low PC20 values (adjusted P = .03) each predicted the expected treatment benefit with fluticasone over montelukast regarding time to first exacerbation. No phenotypic characteristics predicted treatment benefits for montelukast over fluticasone for either outcome. Conclusions: Physicians treating children with a parental history of asthma, increased eNO levels, low PC20 values, or a history of ICS use can expect the best long-term outcomes with ICS therapy compared with treatment with leukotriene receptor antagonists.

KW - Asthma

KW - biomarkers

KW - exhaled nitric oxide

KW - fluticasone propionate

KW - inhaled corticosteroids

KW - montelukast

KW - pulmonary response

UR - http://www.scopus.com/inward/record.url?scp=59449092817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449092817&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2008.11.016

DO - 10.1016/j.jaci.2008.11.016

M3 - Article

C2 - 19121860

AN - SCOPUS:59449092817

VL - 123

SP - 411

EP - 416

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 2

ER -